Treatment for Mycoplasma genitalium
For uncomplicated M. genitalium infection, treat with doxycycline 100 mg orally twice daily for 7 days followed by azithromycin 500 mg on day 1, then 250 mg daily on days 2-5 if macrolide-susceptible; use moxifloxacin 400 mg daily for 7-10 days for macrolide-resistant infections. 1
Critical Context: This is NOT Gonorrhea or Chlamydia
All the provided CDC guidelines from 1998-2010 2, 3, 2, 3, 2, 3, 2, 4 address gonorrhea and chlamydia treatment—not M. genitalium. These organisms require completely different treatment approaches and should not guide M. genitalium management.
Evidence-Based Treatment Algorithm
Step 1: Confirm Diagnosis and Resistance Testing
- M. genitalium requires nucleic acid amplification testing (NAAT) for diagnosis 1, 5
- Macrolide resistance testing is essential when available—over 55% of infections show macrolide resistance 1, 6
- Fluoroquinolone resistance (parC mutations, especially S83I) is increasing and predicts moxifloxacin failure 7
Step 2: First-Line Treatment Based on Resistance Profile
For macrolide-susceptible or unknown resistance status:
- Doxycycline 100 mg orally twice daily for 7 days, THEN
- Azithromycin 500 mg on day 1, followed by 250 mg daily on days 2-5 1, 8
- This achieves 93% cure for macrolide-susceptible infections 7
Rationale for doxycycline lead-in: While doxycycline alone cures only 30-40%, it reduces organism load and decreases selection of macrolide resistance 1, 5, 8
For macrolide-resistant infections:
- Doxycycline 100 mg orally twice daily for 7 days, THEN
- Moxifloxacin 400 mg daily for 7-10 days 1, 8
- Achieves 85% overall cure, but 98.3% cure if parC wild-type 7
Step 3: Complicated Infections (PID, Epididymitis)
Step 4: Treatment Failures (Third-Line Options)
When both azithromycin and moxifloxacin fail:
Option 1: Doxycycline or minocycline 100 mg twice daily for 14 days
Option 2: Pristinamycin 1 g four times daily for 10 days
Emerging option: High-dose tinidazole 2 g daily for 7 days has shown success in case reports for multi-drug resistant infections 10
Critical Pitfalls to Avoid
Resistance Crisis
- Macrolide resistance exceeds 50% in most regions 6, 7
- Single-dose azithromycin 1 g is no longer recommended—it drives resistance and has insufficient cure rates 1, 8
- The parC S83I mutation causes 62.5% treatment failure with moxifloxacin 7
Testing Indications
Test only symptomatic patients or sexual contacts of confirmed cases 1, 5, 11:
- Men: persistent urethritis after gonorrhea/chlamydia treatment
- Women: cervicitis, pelvic inflammatory disease
- Both: proctitis
Do NOT screen asymptomatic persons, including pregnant women without exposure history—this drives unnecessary antibiotic use and resistance 5, 11
Test of Cure
- Recommended 14-28 days after treatment completion 7
- Essential given high treatment failure rates
- Not recommended for asymptomatic persons 5
Partner Management
- All sexual contacts within 60 days should be evaluated and treated 1
- Patients must abstain from sexual activity for 7 days after single-dose therapy or until completion of multi-day regimens 4
When Resistance Testing is Unavailable
If macrolide resistance testing is not accessible (common in the United States 11):
- Use moxifloxacin-based regimen given >50% macrolide resistance prevalence 6, 11
- Doxycycline 100 mg twice daily for 7 days followed by moxifloxacin 400 mg daily for 7-10 days
The 2021 European guideline 1 represents the most current, comprehensive evidence and should guide management, recognizing that resistance patterns continue to worsen and treatment options remain severely limited 9.